Phasic and enduring negative symptoms in schizophrenia: Biological markers and relationship to outcome

Schizophrenia Research

Volumn 45, Issue 3, 2000, Pages 191-201

  Tandon, Rajiv ^a   DeQuardo, John R ^a   Taylor, Stephan F ^a   McGrath, Marlene ^a   Jibson, Michael ^a   Eiser, Alan ^a   Goldman, Mona ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Clinical; Course; Negative symptoms; Neurobiology; Pathophysiology; Schizophrenia

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DEXAMETHASONE; HYDROCORTISONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRAIN VENTRICLE; CLINICAL EXAMINATION; COGNITIVE DEFECT; CORRELATION FUNCTION; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NEGATIVE SYNDROME; NEUROBIOLOGY; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; REM SLEEP; SCHIZOPHRENIA; SLOW WAVE SLEEP; TREATMENT FAILURE;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL MARKERS; BRAIN; CASE-CONTROL STUDIES; CHOLINERGIC ANTAGONISTS; COGNITION; COGNITION DISORDERS; DEXAMETHASONE; FEMALE; FOLLOW-UP STUDIES; HUMAN; HYDROCORTISONE; MALE; MICHIGAN; PROGNOSIS; SCHIZOPHRENIA; SLEEP, REM; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TREATMENT OUTCOME;

EID: 0034722081     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(99)00163-2     Document Type: Article

References (74)

1. Dexamethasone suppression test in positive and negative schizophrenia
2. Negative symptoms in schizophrenia: Definition and reliability
3. Positive and negative symptoms in schizophrenia: A critical appraisal
4. Ventricular enlargement in schizophrenia: Relationship to positive and negative symptoms
5. Evidence for the validity of negative symptoms
6. Measurement of premorbid adjustment in chronic schizophrenia
7. Treatment of negative symptoms
8. Deficit and nondeficit forms of schizophrenia: The concept
9. The treatment of negative symptoms: Pharmacological and methodological issues
10. New views on the course and treatment of schizophrenia
11. Molecular pathology of schizophrenia: More than one disease process
12. Positive and negative symptoms of schizophrenia and the role of dopamine
13. Which characteristics of schizophrenia predate psychosis?
14. Ventricular enlargement in poor-outcome schizophrenia
15. Schizophrenia as a chronic brain process: A study of progressive brain structural change subsequent to the onset of schizophrenia
16. Regional brain volume change over the life-time course of schizophrenia
17. Ventricular enlargement, neuropsychological status, and premorbid function in schizophrenia
18. Comparison of indices of premorbid function in schizophrenia
19. A diagnostic interview: The Schedule for Affective Disorders and Schizophrenia (SADS)
20. The reliability of distinguishing primary versus secondary negative symptoms
21. Electroencephalographic sleep in young, never-medicated schizophrenics
22. The new atypical antipsychotic medications
23. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine
24. Positive and negative syndromes in schizophrenia as a function of chronicity
25. The positive-negative distinction in drug-free schizophrenic patients: Stability, response to neuroleptics, and prognostic significance
26. Longitudinal course of negative symptoms in schizophrenia
27. Electroencephalographic sleep in schizophrenia: A critical review
28. Sleep abnormalities in schizophrenia: Pathophysiological significance
29. Slow-wave sleep deficit in schizophrenia: Pathophysiological significance
30. A longitudinal study of EEG sleep in schizophrenia
31. Delta sleep deficits in schizophrenia
32. Superior temporal gyrus and the course of schizophrenia: Progressive, static, or reversible?
33. Development, disease and degeneration in schizophrenia: A unitary pathophysiological model
34. Assessing the effects of atypical antipsychotics on negative symptoms
35. The biology of pathophysiology of negative symptoms
36. A path-analytic approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients
37. Neurobiology and neuroplasticity in schizophrenia
38. Brief Psychiatric Rating Scale
39. Negative symptomatology in schizophrenia: A conceptual and empirical review
40. Clinical predictors of one-year outcome in schizophrenia
41. Schizophrenia and the myth of intellectual decline
42. Deficit symptoms in schizophrenia: Negative symptoms versus neuroleptic-induced deficits
43. Negative symptoms in schizophrenia: Assessment of the effect of risperidone
44. Research Diagnostic Criteria (RDC): Rationale and reliability
45. The diagnosis and understanding of schizophrenia III: Speculations on the processes that underlie schizophrenic symptoms and signs
46. Prediction of outcome in schizophrenia III. Five-year outcome and its predictors
47. Cholinergic hyperactivity and negative schizophrenic symptoms
48. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia
49. Conclusion: Is integration possible?
50. Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement and outcome
51. Muscarinic cholinergic hyperactivity in schizophrenia: Relationship to positive and negative symptoms
52. Electroencephalographic sleep abnormalities in schizophrenia
53. Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: A replication
54. Positive and negative symptoms covary during closapine treatment in schizophrenia
55. The pathophysiology of positive and negative symptoms in schizophrenia
56. Relationship between DST nonsuppression and shortened REM latency in schizophrenia
57. Cholinergic aspects of schizophrenia
58. Moving beyond findings: Constructs and model-building in schizophrenia
59. Neurobiology of schizophrenia
60. The cholinergic system in schizophrenia reconsidered: Anticholinergic modulation of sleep and symptom profiles
61. Antipsychotics from theory to practice: Integrating clinical and basic data
62. Neuropsychological function and REM sleep in schizophrenic patients
63. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine
64. Effect of pimozide on positive and negative symptoms in schizophrenic patients: Are negative symptoms state-dependent?
65. Course of psychopathology, cognition, and neurobiological abnormality in schizophrenia: Developmental origins and amelioration by antipsychotics
66. Early cerebro-craniofacial dysmorphogenesis in schizophrenia: A lifetime trajectory model from neurodevelopmental basis to 'neuroprogressive' process
67. Abnormal rapid eye movement latencies in schizophrenia
68. Sleep and schizophrenia